Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 3Leukemia 2Triple Negative Breast Neoplasms 1Recurrence 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Melanoma 1Lymphoma 1Lung Neoplasms 1Estrogen Receptor Positive Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 33Cyclophosphamide 29venetoclax 18fludarabine 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × capivasertib × Clear all
NCT07175415 2025-09-16

HEM-iSMART E

Princess Maxima Center for Pediatric Oncology

Phase 1/2 Not yet recruiting
42 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡